Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SWShunqing WangHCHong ChangJCJin Chen

Discussion

Loading...

Member takes

Overview

Interim analysis reveals VSA012 improves hemoglobin levels in 75% of PNH patients, indicating its potential therapeutic role.

Key Points

  • Efficacy findings indicate a 43.5% increase in hemoglobin levels at D56 in PNH patients treated with VSA012.
  • Safety data show no serious adverse events or injection site reactions observed in participants treated with VSA012.
  • An open-label, Phase Ib clinical trial analyzed VSA012's effects on safety and pharmacodynamic parameters in PNH patients.
  • These results support further investigation of VSA012's long-term benefits in addressing significant unmet needs in PNH therapy.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0e2https://doi.org/10.1182/blood-2025-381
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)2025
  2. 2LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks2025
  3. 3Efficacy and safety of NTQ5082 monotherapy in complement-inhibitor-Naïve patients with paroxysmal nocturnal hemoglobinuria: A proof-of-concept, multicenter, randomized, open-label phase 2 study2025
  4. 4KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.2025 · 1 citations
  5. 5Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis2025